How we approach the use of sirolimus and new agents: Medical therapy to treat vascular anomalies.
Pediatr Blood Cancer
; 69 Suppl 3: e29603, 2022 08.
Article
en En
| MEDLINE
| ID: mdl-35253343
ABSTRACT
Vascular anomalies (VAs) are a heterogeneous group of primarily congenital tumors and malformations. The International Society for the Study of Vascular Anomalies (ISSVA) has developed a standard classification of these disorders, creating a uniform approach to their diagnosis. Recent discoveries evaluating the genetic causes of VAs have revealed that they are due to mutations in cancer pathways, including the PI3K/AKT/mTOR and RAS/MAPK/MEK pathways. These discoveries have led to improved phenotype-genotype correlation and have expanded medical therapy for this group of unique disorders.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Sirolimus
/
Malformaciones Vasculares
Límite:
Humans
Idioma:
En
Revista:
Pediatr Blood Cancer
Asunto de la revista:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Año:
2022
Tipo del documento:
Article
País de afiliación:
Estados Unidos